心房动和癌症之间的交叉联系:一个治疗难题
Ermanno Nardi1, Ciro Santoro2, Maria Prastaro1
1Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Cardio-oncology (London, England)
|August 7, 2024
概括
由于炎症和癌症治疗,心房动 (AF) 在癌症患者中更为普遍. 在这个人群中,管理AF需要量身定制的抗凝策略,以平衡凝血和出血的风险.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
背景情况:
- 在患有恶性瘤的患者中,心房动 (AF) 更频繁地发生.
- 炎症和癌症治疗 (化疗,放射治疗,手术) 会加剧AF风险.
- 在患有AF的癌症患者中观察到高血栓栓塞和出血事件的发生率.
研究的目的:
- 为了阐明癌症患者的AF机制.
- 审查当前针对该特定人群的AF管理策略.
- 突出抗凝药治疗决策中的挑战.
主要方法:
- 文献综述侧重于恶性瘤和心房动之间的相互作用.
- 分析癌症和AF之间的病理生理机制.
- 评估现有证据和临床指导方针,用于AF的癌症患者的抗凝药.
主要成果:
- 癌症相关的炎症和治疗副作用是AF的关键驱动因素.
- 已确定的风险评分 (CHA2DS2-VASc,HAS-BLED) 在癌症患者中具有有限的适用性.
- 在这种群体中,抗凝血管理是复杂的,需要个性化的方法.
结论:
- 了解癌症中的AF机制对于有效的预防和护理至关重要.
- 针对AF的癌症患者需要量身定制的抗凝策略.
- 需要进行进一步的研究,以完善这个脆弱群体的风险评估和治疗方案.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Disturbances in Heart Rhythm
924
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
924
Anticoagulant Drugs: Low-Molecular-Weight Heparins
657
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
657
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
502
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
502
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


